Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000-2013.

Beinortas T, Tavorienė I, Žvirblis T, Gerbutavičius R, Jurgutis M, Griškevičius L.

BMC Cancer. 2016 Mar 8;16:198. doi: 10.1186/s12885-016-2238-9.

2.

Unique composite hematolymphoid tumor consisting of a pro-T lymphoblastic lymphoma and an indeterminate dendritic cell tumor: evidence for divergent common progenitor cell differentiation.

Buser L, Bihl M, Rufle A, Mickys U, Tavoriene I, Griskevicius L, Tzankov A.

Pathobiology. 2014;81(4):199-205. doi: 10.1159/000365396. Epub 2014 Sep 11.

PMID:
25228298
3.

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.

Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; ANAHYDRET Study Group.

Blood. 2013 Mar 7;121(10):1720-8. doi: 10.1182/blood-2012-07-443770. Epub 2013 Jan 11.

Supplemental Content

Loading ...
Write to the Help Desk